Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.

Abstract

The majority of patients with subependymal giant cell astrocytoma (SEGA) have tuberous sclerosis complex (TSC). In such patients, the mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to induce responses. Isolated SEGA have been reported in patients without clinical or genetic features of TSC. The treatment of these patients with everolimus has not previously been reported. We treated a patient with a recurrent isolated SEGA with an mTOR inhibitor. The patient tolerated therapy well and had a sustained complete remission. MTOR inhibitors may be useful for the treatment of isolated SEGA. Further study is warranted.

• Authors: Deepika Appalla, Andres Depalma, Stanley Calderwood
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 63 Issue 7 Pg. 1276-8 (07 2016) ISSN: 1545-5017 [Electronic] United States
• PMID: 26929034 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2016 Wiley Periodicals, Inc.

Chemical References

• Everolimus
• MTOR protein, human
• TOR Serine-Threonine Kinases

Topics

• Astrocytoma (diagnostic imaging, drug therapy, enzymology)
• Brain Neoplasms (diagnostic imaging, drug therapy, enzymology)
• Child
• Everolimus (administration & dosage)
• Humans
• Male
• Remission Induction
• TOR Serine-Threonine Kinases (antagonists & inhibitors)
• Tuberous Sclerosis